1 ***TITLE***

2 **Epithelial-to-mesenchymal transition lowers the cholesterol pathway, which**
 3 **influences colon tumors differentiation.**

4

5 ***RUNNING TITLE***

6 **Epithelial-to-mesenchymal transition regulates the cholesterol pathway and colon**
 7 **cancer differentiation**

8

9

10 ***AUTHORS' LIST***

11 Anaïs Aulas^{1*}, Maria Lucia Liberatoscioli^{1*}, Pascal Finetti¹, Olivier Cabaud¹, David J.
 12 Birnbaum^{1,2}, Daniel Birnbaum^{1#}, François Bertucci^{1,3#} & Emilie Mamessier^{1#}

13

14 ***AUTHORS' CONTRIBUTION and notes***

15 AA, FB, DB and EM designed the study. AA, MLL, and OC performed experiments. PF,
 16 MLL and FB did the biocomputational analyses. DJB provided samples and clinical
 17 rationale. FB, DJB, DB proofread the manuscript. AA, MLL and EM designed the figures
 18 and wrote the manuscript. co-authorship: * AA and ML are co-first authors. # DB, FB
 19 and EM are co-last authors.

20

21 ***AFFILIATION***

22 ¹ Predictive Oncology Laboratory, Cancer Research Center of Marseille (CRCM),
 23 Inserm U1068, CNRS UMR7258, Institut Paoli-Calmettes, Aix Marseille Université,
 24 Marseille, France.

25 ² Department of Digestive Surgery, Hospital Nord, Aix-Marseille University, Chemin des
 26 Bourrely, 13015, Marseille, France.

³ Oncology Medical unit, Institut Paoli-Calmettes, Aix-Marseille University, Marseille, France.

29

CORRESPONDING AUTHOR

emilie.mamessier@inserm.fr

32

KEY WORDS

Epithelial to mesenchymal transition, EMT, mesenchymal to epithelial transition, MET, colorectal cancer, metastasis, prognosis, cholesterol, survival

36

37

TRANSLATIONAL RELEVANCE (120-150 WORD)

Metastases are the main cause of death of colorectal cancer (CRC) and the major issue in CRC management. Understanding the chain of events that lead to metastasis occurrence is urgent to identify new biomarkers of progression and/or new potential targets. Epithelial to mesenchymal transition (EMT) is a major player in cancer dissemination that remains non-targetable due to its broad involvement in tissue homeostasis. Here, we used a relevant *in vitro* dynamic model to identify the pathways triggered during EMT in CRC and how this might improve tumors classification, prognosis and open therapeutic avenue for this deadly disease. The cholesterol pathway surprisingly popped-out from this model and turned out to be a good prognosis factor of disease-free survival for CRC. Altogether, our results showed that an active EMT program lowers the cholesterol pathway, which further influence the differentiation of colon tumor toward the most aggressive subtypes.

51

52

53 ***ABSTRACT 185 words (current 184)***

54 Colorectal cancer (CRC) is the second cause of death worldwide. Up to 70% of
 55 CRC patients will metastasize. Identify new biomarkers of progression to prevent/delay
 56 disease evolution is urgent. Epithelial-to-mesenchymal transition (EMT) is a major
 57 program engaged during metastasis. We aim at identifying a combination of new genes
 58 that further identify signs of EMT in cancer tissues. We treated HT-29 cells grown in 3D
 59 with an EMT Inducing cocktail, and collect them before during and after treatment. For
 60 each condition, pan-transcriptomic analyses were done. Genes that were both induced
 61 upon EMT induction and inhibited upon EMT release (mesenchymal-to-epithelial
 62 transition or MET) were selected. We identified new genes for EMT-MET programs.
 63 These genes were used to build a metagene that, when applied to a database of
 64 transcriptomic data from primary colorectal tumors (n= 2,239), had an independent
 65 prognosis value. Finally, we submitted this metagene to CMap and identified drugs that
 66 might affect EMT-MET programs. Statins, well-known inhibitors of cholesterol synthesis,
 67 were among them and effectively delayed MET. These data show that cholesterol and
 68 EMT pathways are opposite regulators and impact differently tumor differentiation and
 69 outcome.

70 **INTRODUCTION**

71 Colorectal cancer (CRC) is the third most common cancer and the second cause
72 of death worldwide (International Agency for Research on Cancer, WHO;
73 <http://gco.iarc.fr/today/fact-sheets-cancers>). However, the actual therapeutic
74 management proposed to CRC patients is not sufficient. For now, it consists in the
75 surgical removal of the primary tumor, followed by adjuvant chemotherapy in high-risk
76 cases. Metastases are the main cause of death of CRC patients, and thus the major
77 issue in CRC management. Up to 70% of CRC patients will relapse or metastasize
78 within 5 years following surgery of the primary tumor. The 5-year overall survival for
79 metastatic patients is 14% against 90% for non-metastatic patients [1].

80 Cells prone to metastasis undergo an epithelial-to-mesenchymal transition
81 (EMT), a biological process by which cells are re-programmed, lose their cell-to-cell
82 contacts, polarity and ultimately reshape their cytoskeleton to escape from the initial
83 tumor site [2]. Many works have searched for the initial events that trigger EMT in
84 cancer cells, based on the assumption that targeting EMT inducers might limit
85 metastasis [3, 4]. TGF β , which is a prominent growth factor at primary tumor sites [5, 6],
86 turned up to be a key inducer of the EMT program [7]. However, TGF β inhibition was
87 not successful because of the major involvement of this growth factor in many other
88 physiological functions [5, 6]. Moreover, EMT can be triggered in many ways that go
89 beyond the TGF β pathway alone [8, 9]. We choose to use a combination of different
90 factors known to be involved in the EMT process such as recombinant WNT5A [10, 11],
91 TGF β [12] and neutralizing antibodies against known inhibitors of EMT, such as SFRP1
92 [13, 14], DKK1 [15] and CDH1 [16, 17]. The combination of these factors reproducibly
93 induces an EMT phenotype in epithelial cancer cells cultivated *in vitro* within one week:
94 cells detach from their neighbors, adopt spindle shapes and a migratory potential.
95 Characteristic features of treated cells are a decreased expression of adhesion proteins

96 E-Cadherin and Occludin, whereas Fibronectin and Vimentin expression are enhanced
97 [18-20].

98 The identification of genes specifically activated during the EMT program has
99 been another goal, however difficult to achieve in complex samples such as human
100 tumors. *In vitro* approaches have thus often been privileged. A major common caveat
101 from these approaches was that the cells exposed to the different EMT inducing
102 factors were usually grown flat [6, 15, 21-23]. We know now that signaling pathways of
103 cells grown in 2D are different from those of tissues and that 3D cultures are more
104 relevant [24, 25]. The extensive study from cells grown in 2D most certainly contributed
105 to limit the identification of EMT regulatory factors to components forming the « tip of the
106 iceberg », leaving hidden other potential actors. This limitation led us to study how EMT
107 induction can promote pro-invasive features from colon cancer cells, with the aim of
108 revealing novel EMT-related molecular vulnerabilities, potentially useful as new
109 prognostic factors and/or novel targets.

110 For this, we used a 3D *in vitro* model and a timeline exposition to the EMT-
111 inducing cocktail to study reversible genes involved in EMT and Mesenchymal-to-
112 Epithelial Transition (MET) programs. From the genes identified, we build a metagene
113 and tested its prognostic value in a large database of CRC samples, annotated with
114 clinical data. Finally, still using these genes, we searched for FDA approved drugs that
115 might influence the EMT-MET programs and found that statins alter the execution of the
116 EMT program.

MATERIAL& METHODS

Cell culture

HT29 cells were obtained from the ATCC[®] Human Cell Lines (ATCC, Manassas, VA, USA) and cultured using Dulbecco Modified Eagle Medium (DMEM, GIBCO, Waltham, MA, USA) with 10% Fetal Calf Serum (FCS, Eurobio, Les Ulis, France) in 5% CO₂ at 37°C. Classical 2D cell cultures were seeded in Falcon[®] 6-well, whereas spheroids culture were seeded in Cell Carrier Spheroid ULA 96-well Microplates™ (PerkinElmer, Waltham, MA, USA). For EMT induction, cells were plated 2 days in regular media before to be supplemented with StemXVivo[®] EMT Inducing Media Supplement (R&D, Minneapolis, MN, USA) at 1X concentration for the indicated time. Cells were treated with lovastatin and simvastatin (Sellekchem, Houston, TX, USA) at indicated concentration and time.

Western Blotting

Cells were scraped and lysed in RIPA buffer (150 mM NaCl, 50 mM Tris, pH 7.4, 1% Triton X-100, 0.1% SDS, 1% sodium deoxycholate) supplemented with HALT protease inhibitor 1X (Thermo Fisher Scientific, Waltham, MA, USA), incubated for 10 min on ice, and centrifuged at 13800 g. Supernatants were collected and quantified with Bradford Protein Assay kit (Thermo Fisher Scientific, Waltham, MA, USA). NuPAGE[®] LDS Sample Buffer (Invitrogen, Carlsbad, CA, USA) was added to samples to 1X final concentration. Samples were boiled at 95 °C for 5 min, loaded into acrylamide/bisacrylamide gels and transferred to nitrocellulose membrane (GE Healthcare, Chicago, IL, USA). Membranes were blocked using PBS 0.1% tween 5% fat free milk for at least 30 min and incubated with primary antibodies diluted in PSB 5% normal horse serum overnight at 4 °C (**Table S1**). The following day, membranes were incubated with HRP coupled secondary antibodies diluted in PSB 5% normal horse serum for 1 h at room temperature (**Table S1**). Blots were visualized by addition of ECL

Western Blotting Substrate (Thermo Fisher Scientific, Waltham, MA, USA) following manufacturer's instructions. Blots were revealed using the imaging system ChemiDoc MP (BioRad, Hercules, CA, USA).

RNA extraction

Total RNA was extracted from the HT29 spheroids using the RNeasy Mini Kit (Qiagen, Hilden, Germany) following the manufacturer's instruction. The quality was tested using an Agilent Bioanalyzer (Agilent, Santa Clara, CA, USA).

Gene expression profiling of treated and untreated HT29 spheroids

Profiling was done using Affymetrix GeneChip HuGene 2.0 ST microarrays according to manufacturer instructions (Affymetrix, Thermo Fisher, Waltham, MA, USA). Expression data were analyzed by Robust Multichip Average (RMA) [26] in R using Bioconductor and associated packages. Prior to analysis, log2-transformed data were filtered out to exclude poorly expressed genes, defined as genes having a median expression level across all samples lower than the first quartile range. Data filtering resulted in 17,421 annotated genes.

Unsupervised analysis, applied to the 3,131 genes with standard deviation (SD)>0.25, was performed with the Cluster program [27] using Pearson correlation and average linkage clustering as parameters. Results were displayed using TreeView program [27]. Robustness of clusters was assessed with the R-package pvclust [28] with identical clustering parameters and 100 bootstrap replications. Ontology analysis of the gene clusters was based on GO biological processes of the Database for Annotation, Visualization and Integrated Discovery (DAVID; <http://david.abcc.ncifcrf.gov/>). The Consensus Molecular Subtype (CMS) classification [29] was applied to each cell culture condition by using the CMScaller tool from Eide et al. [30], providing a CMS score for each subtype (CMS1, CMS2, CMS3, and CMS4) to each condition.

Supervised analyses between the different cell culture conditions was applied by using Gene Set Enrichment Analysis (GSEA) (<http://www.broadinstitute.org/gsea/>) in order to identify the differential biological pathways. Analysis was focused on the 50-hallmark gene sets from the MSigDB v7.0 Molecular Signatures Database (<https://www.gsea-msigdb.org/gsea/msigdb>). We used the class differential metric to rank the filtered genes, weighted enrichment statistic for computing enrichment score (ES) of each gene set tested and 1000 permutations to evaluate significance as parameters for the GSEA. Significant gene sets were defined by a False Discovery Rate (FDR)-corrected p-value <0.01. Metagenes from the significant gene sets were computed as the mean expression of core genes defined by the GSEA analysis.

Gene expression profiling of human cancer colon samples

We built a large database gathering our own data set and 10 publicly available sets as described [26]. These latter had been collected from the National Center for Biotechnology Information (NCBI)/Genbank GEO, ArrayExpress and TCGA databases (**Table S2**). Samples had been profiled using DNA microarrays (Affymetrix, Thermo Fisher, Waltham, MA, USA) or Illumina RNA sequencing (United kingdom, Cambridge). The whole data set included 2,239 primary colon cancer samples in the final analysis. Their clinicopathological characteristics are summarized in **Table 1**. The pre-analytic data processing and data analysis were done as previously described [26]. The CMS classification and the metagenes identified by supervised analyses in the HT29 cells were applied to each data set separately [29]. For these latter, the natural score of 0 was used as threshold to define a sample as “positive” (score>0) or “negative” (score<0).

Connectivity Map interrogation

Finally, in order to identify potential therapies, we applied the Connectivity Map (CMap) analysis [31]. This analysis contains a perturbation-driven gene expression dataset of over a million of gene expression signatures associated with molecule compounds and genetic perturbations treatment on human cells. CMap (<https://clue.io/cmap>) searched for, among the L1000 signatures, the perturbagen's signatures that give significant correlation with those genes included in our two interest metagenes given by connectivity scores. The tested signatures were limited to those with a well-defined mechanism of action of treatment compounds, corresponding to 10,847 signatures of 3,248 drugs through 57 cultured human cell lines. The significance threshold of the normalized connectivity score (ncs) was adjusted p-value <0.001. Because each drug has been used through multiple different culture conditions, we aggregated the significant signatures by drug class, computed for each class the average of normalized connectivity scores (average ncs) and assessed its statistical significance using one sample Student t-test.

Statistical analysis

Correlations between the "EMT-CHL model"-based classes and the clinicopathological variables were calculated with the Student's t-test for the continuous variables and the Fisher's exact test for the binary variables. The survival endpoint was relapse-free survival (RFS) calculated from the date of diagnosis until the date of relapse. The follow-up was measured from the date of diagnosis to the date of last news for event-free patients. Survival was calculated using the Kaplan-Meier method and curves were compared with the log-rank test. Univariate and multivariate analyses were done using Cox regression analysis (Wald test). The variables tested in univariate analysis included patients' age (> vs. ≤50 years) and gender (male vs. female), anatomic location (proximal vs. distal colon), pathological stage (2, 3, 4 vs. 1), pathological grade (2, 3 vs. 1), CMS molecular subtypes (CMS2, CMS3, CMS4 vs. CMS1), and the "EMT-CHL

model"-based classes ("high-risk" vs. "low-risk"). Multivariate analysis incorporated all variables with a p-value inferior to 5% in univariate analysis. The likelihood ratio (LR) tests were used to assess the prognostic information provided beyond that of each metagene included in the Cox model, assuming a χ^2 distribution. Changes in the LR values (LR- $\Delta\chi^2$) quantified the relative amount of information of one Cox model compared with another. In order to build a prognostic Cox model for RFS combining our two metagenes, we randomly split the 1,837 informative primary samples in two sets, training and validation sets. The training set was composed of a quarter of the samples (n=450) and allowed to build the model. This model was then applied to the validation set composed of the 1,387 remaining samples, to estimate the robustness of the predictor. All statistical tests were two-sided at the 5% level of significance. Statistical analysis was done using the survival package (version 2.30) in the R software (version 3.5.2).

RESULTS

The EMT-inducing cocktail induces reversible loose micro-tissues, consistent with EMT and EMT-MET-like programs

The EMT-inducing cocktail used for this study is a potent inducer of EMT [18, 20, 32-35]. However, growth in 2D on plastic dishes offers unnatural growth kinetics and cells attachment, thus altering adhesion and related signaling pathways, and potentially biasing and/or masking EMT-induced signals. To study EMT induction in a more physiologic and dynamic model, we looked at the reversible effects of an EMT-inducing cocktail on cells grown in 3D as spheroids. We induced EMT on several colon cancer cell lines (HT29, HCT116, SW480). The most striking phenotype was observed with the HT29 colon cancer cell line, and we choose to continue with them. We used three conditions on HT29 spheroids: HT29 spheroids grown without any treatment (Baseline condition), HT29 spheroids exposed to the EMT-inducing cocktail for 5 days to induce EMT, and HT29 spheroids exposed to the EMT-inducing cocktail for 5 days, washed, then incubated for an additional 4 days without any treatment to mimic a sequential EMT followed by a MET process (**Figure 1A**).

In the absence of any specific treatment (Baseline), the spheroids continued to grow as dense spheroids during the whole protocol (**Figure 1B, top row**). When the EMT-inducing cocktail was added to the media (EMT condition) the spheroids became loose, with round cells at the periphery of the spheroid core, already after 3 days of treatment (**Figure 1B, middle row**). In the EMT-MET condition, the first 5 days were similar to the EMT condition, then during the following 3 days, *i.e.* after the removal of the EMT-inducing cocktail (MET-*like* program), the individualized round cells progressively reintegrated the spheroids core to form a homogeneous and compact spheroid (**Figure 1B, bottom row**).

We verified that the EMT-like phenotype induced by the EMT-inducing cocktail actually induced known EMT factors. We studied key molecules of EMT at the protein

level by western blotting. We compared Baseline microtissues samples to EMT and EMT-MET samples. The EMT-inducing cocktail induced the expression of specific mesenchymal proteins such as Fibronectin, ZEB1 and Vimentin (**Figure 1C**). All these markers went back to their respective baseline after removal of the EMT-inducing cocktail (*i.e.* Baseline condition and EMT-MET are similar). Conversely and as expected, the epithelial marker OCCLUDIN was downregulated during the EMT process.

Thus the EMT-inducing cocktail induced reversible macroscopic changes, phenotypically compatible with an EMT program induction.

Transcriptomic analysis confirms the activation of EMT and EMT-MET programs in spheroids treated with the EMT-inducing cocktail

We surmised that the effect of the EMT-inducing cocktail was not limited to known EMT markers. To identify broad biological pathways activated by the EMT-inducing cocktail in treated spheroids, we performed DNA microarray analyses (Affymetrix™ GeneChip Human Gene 2.0 ST Assay) from the three conditions described above (Baseline, EMT, and EMT-MET, **Figure 1A**) and compared their expression profiles. Analyses were done at day 5 for Baseline and EMT samples and at day 7 for EMT-MET samples. Each condition was tested in triplicate. Unsupervised hierarchical clustering revealed, as expected, three distinct and coherent clusters, corresponding to each of the three conditions tested: Baseline, EMT, and EMT-MET (**Figure 1D**). The EMT and EMT-MET conditions were closer to each other than to the Baseline condition (**Figure 1D**). This is coherent with the fact that at day 7, spheroids were not fully back to baseline yet (**Figure 1B**). Visual inspection of gene clusters revealed two clusters, thereafter designated 1 and 2, that were deregulated from the Baseline condition to the EMT condition and showed opposite deregulation from the

EMT condition to the EMT-MET condition. Cluster 1 was upregulated in EMT condition and downregulated in EMT-MET condition: it included 198 genes with minimal Pearson correlation equal to 0.74. In term of ontologies, the DAVID GO biological processes associated with this cluster included cell migration ($p=1.15E-04$), extracellular matrix organization ($p=1.78E-04$), regulation of cell adhesion ($p=7.87E-05$) and wound healing pathways ($p=3.84E-03$). By contrast, Cluster 2 was downregulated in EMT condition and upregulated in EMT-MET condition: it included 296 genes with minimal Pearson correlation equal to 0.75. The GO biological processes represented in this cluster were related to cholesterol biosynthetic process ($p=4.42E-20$), lipid metabolism ($1.6E-02$) and metabolic pathways ($p=1.22E-02$) (**Figure 1D, Table S3**). Thus, transcriptional analysis of the EMT and EMT-MET programs induced in the spheroids revealed a list of candidates and associated molecular pathways whose expression was modulated and reversible. Expected pathways related to cell migration and adhesion, known to be central to this reversible phenomenon, validated the biological relevance of our *in vitro* model that also revealed unexpected genes and pathways.

Spheroids treated with the EMT-inducing cocktail shift toward the mesenchymal consensus molecular subtypes (CMS4)

The CMS classification distinguishes four subtypes of CRC based on the tumor's prominent biological profiles, each subtype having a defined prognosis: the CMS1 microsatellite instability/immune subtype (hyper-mutated, microsatellite unstable and strong immune activation), the CMS2 canonical subtype (epithelial with marked WNT and MYC signaling activation), the CMS3 metabolic subtype (epithelial and neat metabolic dysregulation), and the CMS4 mesenchymal subtype (prominent TGF β activation, stromal invasion and angiogenesis) [36]. We surmised that genes expressed in the CMS4 mesenchymal class may be enriched in the EMT-inducing cocktail treated spheroids, but neither in the Baseline nor in the EMT-MET spheroids.

The CMS classification applied to the 3 cell culture conditions (Baseline, EMT and EMT-MET conditions) defined a CMS score for each subtype (CMS1, CMS2, CMS3, and CMS4) and for each cell culture condition (Baseline, EMT and EMT-MET conditions). As shown in **Figure 1E**, the prevalent score of Baseline samples corresponded to the CMS3 class (mean CMS3 score = 0.332). This result is coherent with a previous CMS classification of HT29 cells [37]. When compared with Baseline conditions, EMT samples showed a decrease of the CMS3 score ($p=1.22E-02$) and an increase of the CMS4 score ($p=9.58E-03$). Enrichment in CMS4 score (*i.e.* mesenchymal genes) was concordant with the induction of EMT. After the EMT-inducing cocktail removal (EMT-MET samples), the score for the CMS4 class decreased, as expected, while the score for the CMS2 class increased compared to the Baseline condition ($p=2.57E-02$). This result showed that a pro-epithelial program (starting with a switch toward the CMS2 subtype) was re-activated once the EMT-inducing cocktail was removed from the culture. Altogether, the results showed that HT29 cells grown as spheroids and exposed to an EMT inducer activated a physiologic pro-mesenchymal transcriptomic program (the shift toward the CMS4 mesenchymal subtype) and that this process was reversible toward a pro-epithelial phenotype when the EMT inducer was removed. This observation further validated the relevance of our *in vitro* model.

EMT genes, Bile Acid Metabolism and Cholesterol Homeostasis hallmark gene sets are affected during the EMT and EMT-MET programs

To identify the biological pathways reversibly altered during the EMT process, we did a supervised analysis between the different cell culture conditions. Two comparisons were done: EMT *versus* Baseline samples (EMT induction), and EMT-MET *versus* EMT samples (MET induction). From these signatures, we used GSEA applied to the 50-hallmark gene sets from the MSigDB Molecular Signatures Database.

Our objective was to identify and select gene sets that showed an opposite pattern of variation in those two comparisons. Sixteen gene sets were differentially regulated at least in one comparison ($q\text{-value} < 1\%$) (**Figure 2A, grey background**), and three of them were significantly up- or downregulated in the EMT samples and returned to baseline levels in the EMT-MET samples (**Figure 2A, white background**). The “*Epithelio-Mesenchymal transition*” gene set was composed of 23 core genes upregulated in the EMT compared to Baseline samples ($q\text{-value} = 5.61\text{E-}03$) and 39 core genes downregulated in the EMT-MET compared to EMT samples ($q\text{-value} < 1.00\text{E-}03$) (**Table S4, columns 3 and 10 respectively, orange background**). The *Bile Acid Metabolism* gene set was composed of 33 core genes downregulated in the EMT compared to Baseline samples ($q\text{-value} = 9.16\text{E-}03$) and 33 core genes upregulated in the EMT-MET compared to EMT samples ($q\text{-value} = 1.62\text{E-}03$) (**Table S4, columns 3 and 10 respectively, green background**). The *Cholesterol Homeostasis* gene set was composed of 31 core genes downregulated in the EMT samples compared to Baseline samples ($q\text{-value} < 1.00\text{E-}03$) and 28 core genes upregulated in the EMT-MET compared to EMT samples ($q\text{-value} = 2.64\text{E-}03$) (**Table S4, columns 3 and 10 respectively, yellow background**). Among the core genes: 14 genes were retained in the “*Epithelio-Mesenchymal transition*” gene set, 17 in the “*Bile Acid Metabolism*” gene set, and 21 in the “*Cholesterol Homeostasis*” gene set, representing a total of 52 genes (**Figure 2B, Table S4 column 18**).

We built 3 independent metagenes from each of these three core gene sets. As shown in **Figure 2C**, each metagene was robust enough to distinguish the HT29 samples according to their respective condition (Baseline, EMT, and EMT-MET): the “*Epithelio-Mesenchymal transition*” metagene score was the highest in the EMT samples compared to the Baseline samples ($p\text{-value} = 3.22\text{E-}06$) and to the EMT-MET samples ($p\text{-value} = 1.25\text{E-}05$). The “*Bile Acid Metabolism*” and the “*Cholesterol Homeostasis*” metagene scores were the lowest in the EMT samples compared to the

Baseline samples (p-value=2.08E-04 and p-value=1.70E-05 respectively) and to the EMT-MET samples (p-value=2.08E-04 and p-value=1.70E-05, respectively). Altogether, this procedure allowed us to identify 52 genes reversibly regulated during the EMT and the EMT-MET programs. Those genes, when separated into three distinct metagenes based on their hallmark ontology, could also individually distinguished an active from an inactive EMT program in tumor cells.

***In vitro* derived metagenes show independent prognostic value in colon cancer**

Given the known link between EMT and the metastatic process, we assessed the prognostic value of each metagene (positive *versus* negative) in a large gene expression database of untreated human colon cancer samples (**Table S2**). This base included 2,239 clinically annotated primary colon tumors, including 1,837 with available Recurrence-Free Survival (RFS) data. In univariate analysis, the “*Bile Acid Metabolism*” metagene was not prognostic (**Figure 3A**). By contrast, the positive “*Epithelio-Mesenchymal transition*” metagene (HR=1.37, [95CI 1.14-1.64]; p=6.28E-04, Wald test) and negative “*Cholesterol Homeostasis*” metagene (HR=1.25, [95CI 1.04-1.49]; p=1.64E-02, Wald test) were associated with shorter RFS, and showed independent prognostic value in multivariate analysis (**Figure 3B**). The **Figure 3C** shows the Kaplan-Meier curves for RFS in four groups defined by each significant metagene: the 5-year RFS was 77% (95%CI 73-82) in the “*Epithelio-Mesenchymal transition*”-negative/“*Cholesterol Homeostasis*”-positive group, 71% (95%CI 67-77) “*Epithelio-Mesenchymal transition*”-negative/“*Cholesterol Homeostasis*”-negative group, 70% (95%CI 65-75) in the “*Epithelio-Mesenchymal transition*”-positive/“*Cholesterol Homeostasis*”-positive group, and 65% (95%CI 60-70) in the “*Epithelio-Mesenchymal transition*”-positive/“*Cholesterol Homeostasis*”-negative group (p=4.61E-04; log-rank test). Such prognostic complementarity was confirmed using the likelihood ratio (LR) test (**Table S5**): the “*Cholesterol Homeostasis*” metagene added prognostic information

to that provided by “*Epithelio-Mesenchymal transition*” metagene ($\Delta\text{LR-X2}=5.21$, $p=2.24\text{E-}02$), and the “*Epithelio-Mesenchymal transition*” metagene added prognostic information to that provided by the “*Cholesterol Homeostasis*” metagene ($\Delta\text{LR-X2}=13.26$, $p=2.72\text{E-}04$).

The model combining the “Epithelial Mesenchymal Transition” and the “Cholesterol Homeostasis” metagenes is a robust prognostic factor for RFS in CRC

Based on these results, we built a multigene model combining the “*Epithelial Mesenchymal Transition*” (14 genes) and the “*Cholesterol Homeostasis*” (21 genes) metagenes, thereafter designated “EMT-CHL model”. We randomly split the 1,837 informative primary samples in two sets: a training set composed of a quarter of the samples ($n=450$) to build the model, and a validation set composed of the 1,387 remaining samples (**Table 2**) to test its robustness. As expected, in the training set, the model showed a difference between the 5-year RFS of the “low-risk” class (75% [CI95 69-83]; $n=225$) and the “high-risk” class (66% [CI95 59-74]; $n=225$; $p=9.93\text{E-}03$, log-rank test; (**Figure 3D, left panel**). Importantly, the model maintained its prognostic value in the validation set, with 74% 5-year RFS in the “low-risk” class (CI95 70-78; $n=672$) versus 68% in the “high-risk” class (CI95 64-72; $n=71$; $p=1.68\text{E-}23$, log-rank test) (**Figure 3D, right panel**).

The correlation of the “EMT-CHL model”-based classes with clinicopathological variables in the validation set are shown in **Table 2**. When compared with the “low-risk” class, the “high-risk” class was associated with more female ($p=2.0\text{E-}03$, Fisher’s exact test), more pathological stage 3 ($p=3.0\text{E-}04$, Fisher’s exact test), and more CMS1 and CMS4 subtypes ($p=3.5\text{E-}33$, Fisher’s exact test). We then compared the prognostic value of our “EMT-CHL model” with that of other clinicopathological factors in the validation set in univariate and multivariate analyses (**Table 3**). The other variables

significant in univariate analysis were the pathological stage ($p=3.1E-10$) and the CMS classification ($p=2.3E-03$, Wald test). In multivariate analysis, the pathological stage and our multigene model ($p=4.0E-02$, Wald test) remained significant but not the CMS classification. Altogether these analyses showed that our “EMT-CHL” model was a robust and independent prognostic factor for RFS in primary colon cancer.

CMap analysis revealed inhibitors and antagonists that might affect the EMT and EMT-MET programs

We then searched for drugs that might affect (promote or inhibit) the plasticity of the EMT and/or EMT-MET programs. We submitted the 35 genes of the EMT-CHL model to Connectivity Map (CMap), which reports the transcriptional responses of human cells to a variety of chemical or genetic perturbations [31]. The resulting connectivity scores reflect the level of agreement between the tested signature and the L1000 profiles/signatures. Analysis was limited to the 10,847 signatures related to treatment compounds with known mechanism of action through 57 cultured human cell lines: 761 signatures had significant correlation (normalized connectivity score (ncs) *i.e.* adjusted p -value <0.001) with the “EMT-CHL” model genes through 47 human cell lines over 309 drugs compounds (representing 145 drug classes; **Table S6**). We aggregated the significant signatures by drug class and computed the average ncs for each class: 98 drug classes were significant. **Table 4** shows the top 15 drug classes identified, which includes antagonists/inhibitors of Dopamine receptor, EGFR, Serotonin receptor, PDGFR, BCR-ABL, ABL, Histamine receptor, KIT, Adrenergic receptor, HMG-CoA reductase (HMGCR), SRC, Calcium channel, Tricyclic antidepressant, Estrogen receptor, and VEGFR. All connectivity scores were negatively correlated with our signature, suggesting that these drugs might interfere with the EMT-MET process.

Blocking enzymes from the cholesterol pathway prevents the execution of the EMT-MET program

We first confirmed that HMGCR and DHCR7 were downregulated during the EMT process and came back to a control level during the MET process due to release of the EMT-inducing treatment (**Figure S1**). From the candidates identified above, we chose to test the HMGCR inhibitors, which directly target the cholesterol pathway. We selected two statins, Lovastatin and Simvastatin, and applied them on 2-days-old organoids (**Figure 4A**). Even at high concentration of each statin, we did not observe any change in the phenotypical aspect of the microtissues when added alone (**Figure 4B, C** for *Simvastatin*) or in co-treatment with the EMT-inducing cocktail (*Data not shown*) compared to the EMT-inducing factor alone. However, when statins were added after a pre-treatment with the EMT-inducing cocktail, *i.e.* during the EMT-MET program (**Figure 4D**), we observed that the treated spheroids maintained a loose EMT-like phenotype instead of reversing to dense spheroids, as those observed with the Baseline situation (**Figure 4E, F**). This result showed that inhibiting the cholesterol pathway after EMT induction prevented the completion of the MET program, in the absence of EMT inducing factors, highlighting the importance of the regulation of the cholesterol pathway during the EMT-MET programs.

Discussion

EMT implication in oncogenesis and metastasis has been extensively studied showing the role of many transcription (e.g. TWIST) and secreted factors (e.g. TGF β). However, progress is necessary to better understand this implication and to provide therapeutic targets [9, 22, 23, 38]. The novelty of our study rely on the combination of the broad induction of EMT using an EMT-inducing cocktail, a 3D model and the timeline approach of EMT-MET induction programs.

This allowed the identification of two sets of genes reversibly regulated during either the induction of EMT or the EMT-MET program. The two key pathways retained for our model comprised genes from the EMT pathway, as expected, but also more surprisingly, genes from the cholesterol pathway. When combined as a multigene model, they showed an independent prognostic value in a large dataset of patients with primary colorectal cancer, highlighting the clinical relevance of our finding.

When analyzed in detail, we found that the 14 genes related to the EMT pathway and reversibly modified in response to the EMT-inducing cocktail were genes induced by TGF β (*PMEPA1*, *CTGF*, *TAGLN*, *CYR61* ...). They have also been involved in cell migration (*TNC*, *IL8*, *TAGLN*, *FLNA*, *SERPINE1*, *MYL9*, *CYR61*, *GPC1*...) in various cancers. At least four of them promoted colorectal liver metastasis through enhancement of the EMT program (*THBS1*, *TAGLN*, *ITGA2*, *FLNA*). Several of them code for surface glycoproteins or integrin-related molecules (*PMEPA1*, *TAGLN*, *SERPINE1*, *THBS1*, *GPC1*). Some or a combination of these genes might be used as biomarkers for EMT to identify CRC patients potentially more at risk to relapse [39-46].

The involvement of the cholesterol pathway inhibition (during EMT) and re-activation (during EMT-MET) is a new and intriguing finding. The 21 genes of the cholesterol metagene code for most (if not all) enzymes responsible for the synthesis of cholesterol (highlighted in red in **Figure 5**). Cholesterol is essential for cell function and

viability. It is a component of the plasma membrane and lipid rafts, a signaling molecule (ligand for estrogen-related receptor alpha (ESRRA)), and a precursor for steroid hormones, Vitamin D and bile acids. The bile acid pathway was also found downregulated during EMT and activated during the EMT-MET programs but did not have prognostic value in our study. Many reports have suggested that cholesterol pathway activation is important for stem cells maintenance in tissues but also for other pro-metastatic function, such as proliferation, survival and resistance to treatment [47]. All these features are associated with pejorative prognosis. Cholesterol synthesis is enhanced in cancer cells compared to normal cells [48, 49]. Additionally, patients with high cholesterol levels have an increased risk for many cancers [48, 49]. But thus far, clinical trials with HMGCR inhibitors (statins) have had mixed results [50, 51]. In our case, activation of the cholesterol synthesis pathway tended to be of better prognosis. Due to its multiple biological roles including in tissue homeostasis, cholesterol might have several roles depending on conditions, cells type or timing. Changes in one of these variables might reveal different functionalities. Compared to previous results, our dynamic model enriched the “EMT field” by highlighting the role of cholesterol regulation in relationship with the triggering of cell detachment signal and cell plasticity. Phenotypic plasticity may provide cancer cells with increased adaptability and resistance, enabling them to respond to a variety of external cues and physiological stresses, including EMT signals. In addition to highlighting the reversibility of the cholesterol pathway activation during EMT-MET programs, we also showed that *in vitro* blockade of the cholesterol pathway altered the execution of the EMT-MET program. One hypothesis is that, in the context of tumor cell motility and migration, EMT requires lowering the synthesis of cholesterol to ensure the destabilization of lipid rafts and/or to allow more flexibility in cell membrane for migration. In this line, in breast and hepatocellular carcinomas, CD44 affinity for cholesterol-rich lipid rafts and retention inside lipid rafts prevent migration [52-56]. Also, statins induce disruption of lipid rafts, impairing tumor cell adhesion, but

enhance invasive and metastatic ability of cancer cells [52-56]. The molecular mechanism involved remains however to be fully elucidated. Altogether, these results suggest that beside or through their lipid lowering property, factors such as statins might also influence complex cell biological programs, during oncogenesis such as EMT.

Similar findings (simultaneous opposite involvement of EMT and cholesterol pathways) in pancreatic ductal adenocarcinoma (PDAC) revealed that cholesterol pathway inhibition induces TGF β signaling and promotes basal differentiation [21]. More specifically, the disruption of cholesterol biosynthesis by *Nsdhl* knockout (in mice) or treatment with statins (in mice and in humans) induces the switch from a glandular to a squamous PDAC subtype (mesenchymal subtype). In line with this, a previous study suggested that human tumor cells belonging to the quasi-mesenchymal/squamous/basal subtype of PDAC utilize transcriptionally-dominated programs to lose their epithelial phenotype during EMT, while those belonging to the classical/pancreatic progenitor/ADEX subtype rely on protein re-localization to lose their epithelial phenotype during EMT [57]. This recent discovery now reveals that this glandular to squamous PDAC switch can occurs *via* the activation of SREBP1, which induces TGF β 1 expression, autocrine TGF β -SMAD2/3 signaling and EMT. In line with this major finding, we showed that inducing EMT in our model can switch a cell line from a CMS3 subtype to a CMS4 mesenchymal subtype using a transcriptionally-dominated program [36], connecting this switch to a more pejorative prognosis. Accordingly, we found that the CMS4 subtype [36] was enriched in the “high-risk” prognostic group, *i.e* “EMT high, Cholesterol down”. It is thus possible that a general mechanism promoting basal/squamous/mesenchymal differentiation with the transcriptional downregulation of the cholesterol pathway and the upregulation of TGF β related genes occurs in multiple tumor types (**Figure 5**). Moreover, it was reported that TGF β -induced mitotic defects in proliferating cells are reversible upon its withdrawal, whereas the acquired genomic abnormalities persist, leading to increased tumorigenic phenotypes. Tumor cells

differentiation might thus result from a different degree of EMT depending on several factors, genetic and non-genetic such as the microenvironment and the various treatments [58].

In parallel, and in line with this hypothesis, it would be of interest to identify patients who received statins prior to their diagnosis of colorectal cancer and test if these patient's tumors are more of the CMS4 subtype. As shown in the PDAC study, this would suggest that the lowering of the cholesterol pathway can indeed influence the subtype of the growing carcinoma, which would be a major discovery in the field. Our *in vitro* data however suggested that cholesterol lowering effects, notably when using statins, occurs only during a specific window to antagonize the MET program. We cannot exclude that a feedback loop between EMT and cholesterol pathways might also exist, which will add a new layer of complexity to this already intricate subject.

References

1. Wang, J., et al., *Metastatic patterns and survival outcomes in patients with stage IV colon cancer: A population-based analysis*. Cancer Med, 2020. **9**(1): p. 361-373.
2. Lamouille, S., J. Xu, and R. Derynck, *Molecular mechanisms of epithelial-mesenchymal transition*. Nat Rev Mol Cell Biol, 2014. **15**(3): p. 178-96.
3. Batlle, E., et al., *The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells*. Nat Cell Biol, 2000. **2**(2): p. 84-9.
4. Cano, A., et al., *The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression*. Nat Cell Biol, 2000. **2**(2): p. 76-83.
5. Yoshida, G.J. and H. Saya, *Molecular pathology underlying the robustness of cancer stem cells*. Regen Ther, 2021. **17**: p. 38-50.
6. Bragado, P., et al., *TGF-beta2 dictates disseminated tumour cell fate in target organs through TGF-beta-RIII and p38alpha/beta signalling*. Nat Cell Biol, 2013. **15**(11): p. 1351-61.
7. Xu, J., S. Lamouille, and R. Derynck, *TGF-beta-induced epithelial to mesenchymal transition*. Cell Res, 2009. **19**(2): p. 156-72.
8. Jayachandran, J., H. Srinivasan, and K.P. Mani, *Molecular mechanism involved in epithelial to mesenchymal transition*. Arch Biochem Biophys, 2021: p. 108984.
9. Thiery, J.P. and J.P. Sleeman, *Complex networks orchestrate epithelial-mesenchymal transitions*. Nat Rev Mol Cell Biol, 2006. **7**(2): p. 131-42.
10. Kanazawa, T., et al., *TLS/FUS-ERG fusion gene in acute lymphoblastic leukemia with t(16;21)(p11;q22) and monitoring of minimal residual disease*. Leuk Lymphoma, 2005. **46**(12): p. 1833-5.
11. Dissanayake, S.K., et al., *The Wnt5A/protein kinase C pathway mediates motility in melanoma cells via the inhibition of metastasis suppressors and initiation of an epithelial to mesenchymal transition*. J Biol Chem, 2007. **282**(23): p. 17259-71.
12. Chruscik, A., V. Gopalan, and A.K. Lam, *The clinical and biological roles of transforming growth factor beta in colon cancer stem cells: A systematic review*. Eur J Cell Biol, 2018. **97**(1): p. 15-22.
13. Ren, J., et al., *SFRP1 inhibits epithelial-mesenchymal transition in A549 human lung adenocarcinoma cell line*. Cancer Biother Radiopharm, 2013. **28**(7): p. 565-71.
14. Chung, M.T., et al., *SFRP1 and SFRP2 suppress the transformation and invasion abilities of cervical cancer cells through Wnt signal pathway*. Gynecol Oncol, 2009. **112**(3): p. 646-53.
15. Duan, H., et al., *TET1 inhibits EMT of ovarian cancer cells through activating Wnt/beta-catenin signaling inhibitors DKK1 and SFRP2*. Gynecol Oncol, 2017. **147**(2): p. 408-417.
16. Yue, B., et al., *LncRNA-ATB mediated E-cadherin repression promotes the progression of colon cancer and predicts poor prognosis*. J Gastroenterol Hepatol, 2016. **31**(3): p. 595-603.
17. Hu, Y., et al., *Epigenetic suppression of E-cadherin expression by Snail2 during the metastasis of colorectal cancer*. Clin Epigenetics, 2018. **10**(1): p. 154.
18. Scheel, C., et al., *Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast*. Cell, 2011. **145**(6): p. 926-40.
19. Tang, Y., et al., *Induction and analysis of epithelial to mesenchymal transition*. J Vis Exp, 2013(78).
20. Liu, Y.L., et al., *Assessing metastatic potential of breast cancer cells based on EGFR dynamics*. Sci Rep, 2019. **9**(1): p. 3395.
21. Gabitova-Cornell, L., et al., *Cholesterol Pathway Inhibition Induces TGF-beta Signaling to Promote Basal Differentiation in Pancreatic Cancer*. Cancer Cell, 2020. **38**(4): p. 567-583 e11.
22. Fazilat, H., et al., *A gene regulatory network to control EMT programs in development and disease*. Nat Commun, 2019. **10**(1): p. 5115.
23. Jia, D., et al., *Testing the gene expression classification of the EMT spectrum*. Phys Biol, 2019. **16**(2): p. 025002.

- 613 24. Chitcholtan, K., et al., *Differences in growth properties of endometrial cancer in three dimensional*
614 *(3D) culture and 2D cell monolayer*. Exp Cell Res, 2013. **319**(1): p. 75-87.
- 615 25. Melissaridou, S., et al., *The effect of 2D and 3D cell cultures on treatment response, EMT profile and*
616 *stem cell features in head and neck cancer*. Cancer Cell Int, 2019. **19**: p. 16.
- 617 26. Irizarry, R.A., et al., *Exploration, normalization, and summaries of high density oligonucleotide array*
618 *probe level data*. Biostatistics, 2003. **4**(2): p. 249-64.
- 619 27. Eisen, M.B., et al., *Cluster analysis and display of genome-wide expression patterns*. Proc Natl Acad
620 Sci U S A, 1998. **95**(25): p. 14863-8.
- 621 28. Suzuki, R. and H. Shimodaira, *Pvclust: an R package for assessing the uncertainty in hierarchical*
622 *clustering*. Bioinformatics, 2006. **22**(12): p. 1540-2.
- 623 29. Bertucci, F., et al., *EndoPredict predicts for the response to neoadjuvant chemotherapy in ER-*
624 *positive, HER2-negative breast cancer*. Cancer Lett, 2014. **355**(1): p. 70-5.
- 625 30. Eide, P.W., et al., *CMScaller: an R package for consensus molecular subtyping of colorectal cancer*
626 *pre-clinical models*. Sci Rep, 2017. **7**(1): p. 16618.
- 627 31. Subramanian, A., et al., *A Next Generation Connectivity Map: L1000 Platform and the First*
628 *1,000,000 Profiles*. Cell, 2017. **171**(6): p. 1437-1452 e17.
- 629 32. Siddiqui, A., et al., *Thymidylate synthase is functionally associated with ZEB1 and contributes to the*
630 *epithelial-to-mesenchymal transition of cancer cells*. J Pathol, 2017. **242**(2): p. 221-233.
- 631 33. Druzhkova, I., et al., *E-Cadherin in Colorectal Cancer: Relation to Chemosensitivity*. Clin Colorectal
632 Cancer, 2019. **18**(1): p. e74-e86.
- 633 34. Brodaczewska, K.K., et al., *Metastatic renal cell carcinoma cells growing in 3D on polyDlysine or*
634 *laminin present a stemlike phenotype and drug resistance*. Oncol Rep, 2019. **42**(5): p. 1878-1892.
- 635 35. Dang, H.X., et al., *Long non-coding RNA LCAL62 / LINC00261 is associated with lung*
636 *adenocarcinoma prognosis*. Heliyon, 2020. **6**(3): p. e03521.
- 637 36. Guinney, J., et al., *The consensus molecular subtypes of colorectal cancer*. Nat Med, 2015. **21**(11): p.
638 1350-6.
- 639 37. Sveen, A., et al., *Colorectal Cancer Consensus Molecular Subtypes Translated to Preclinical Models*
640 *Uncover Potentially Targetable Cancer Cell Dependencies*. Clin Cancer Res, 2018. **24**(4): p. 794-806.
- 641 38. Lavin, D.P. and V.K. Tiwari, *Unresolved Complexity in the Gene Regulatory Network Underlying EMT*.
642 Front Oncol, 2020. **10**: p. 554.
- 643 39. Cheng, M., et al., *FLNA promotes chemoresistance of colorectal cancer through inducing epithelial-*
644 *mesenchymal transition and smad2 signaling pathway*. Am J Cancer Res, 2020. **10**(2): p. 403-423.
- 645 40. Takahashi, Y., et al., *Tumor-derived tenascin-C promotes the epithelial-mesenchymal transition in*
646 *colorectal cancer cells*. Anticancer Res, 2013. **33**(5): p. 1927-34.
- 647 41. Li, J., et al., *The clinical significance of circulating GPC1 positive exosomes and its regulative miRNAs*
648 *in colon cancer patients*. Oncotarget, 2017. **8**(60): p. 101189-101202.
- 649 42. Huang, X., et al., *Snail/FOXK1/Cyr61 Signaling Axis Regulates the Epithelial-Mesenchymal Transition*
650 *and Metastasis in Colorectal Cancer*. Cell Physiol Biochem, 2018. **47**(2): p. 590-603.
- 651 43. Jeong, D., et al., *Cyr61 expression is associated with prognosis in patients with colorectal cancer*.
652 BMC Cancer, 2014. **14**: p. 164.
- 653 44. Bie, Y., et al., *The Crucial Role of CXCL8 and Its Receptors in Colorectal Liver Metastasis*. Dis Markers,
654 2019. **2019**: p. 8023460.
- 655 45. Long, X., et al., *IL-8, a novel messenger to cross-link inflammation and tumor EMT via autocrine and*
656 *paracrine pathways (Review)*. Int J Oncol, 2016. **48**(1): p. 5-12.
- 657 46. Yang, J.D., L. Ma, and Z. Zhu, *SERPINE1 as a cancer-promoting gene in gastric adenocarcinoma:*
658 *facilitates tumour cell proliferation, migration, and invasion by regulating EMT*. J Chemother, 2019.
659 **31**(7-8): p. 408-418.
- 660 47. McCorry, A.M., et al., *Epithelial-to-mesenchymal transition signature assessment in colorectal*
661 *cancer quantifies tumour stromal content rather than true transition*. J Pathol, 2018. **246**(4): p. 422-
662 426.
- 663 48. Vona, R., E. Iessi, and P. Matarrese, *Role of Cholesterol and Lipid Rafts in Cancer Signaling: A*
664 *Promising Therapeutic Opportunity?* Front Cell Dev Biol, 2021. **9**: p. 622908.

49. Beck, B. and C. Blanpain, *Unravelling cancer stem cell potential*. Nat Rev Cancer, 2013. **13**(10): p. 727-38.
50. Krens, L.L., et al., *Statin use is not associated with improved progression free survival in cetuximab treated KRAS mutant metastatic colorectal cancer patients: results from the CAIRO2 study*. PLoS One, 2014. **9**(11): p. e112201.
51. Shao, Y.Y., et al., *Statin Use Is Associated With Improved Prognosis of Colorectal Cancer in Taiwan*. Clin Colorectal Cancer, 2015. **14**(3): p. 177-184 e4.
52. Yang, Z., et al., *Cholesterol inhibits hepatocellular carcinoma invasion and metastasis by promoting CD44 localization in lipid rafts*. Cancer Lett, 2018. **429**: p. 66-77.
53. Babina, I.S., et al., *A novel mechanism of regulating breast cancer cell migration via palmitoylation-dependent alterations in the lipid raft affiliation of CD44*. Breast Cancer Res, 2014. **16**(1): p. R19.
54. Donatello, S., et al., *Lipid raft association restricts CD44-ezrin interaction and promotion of breast cancer cell migration*. Am J Pathol, 2012. **181**(6): p. 2172-87.
55. Murai, T., *The role of lipid rafts in cancer cell adhesion and migration*. Int J Cell Biol, 2012. **2012**: p. 763283.
56. Murai, T., et al., *Low cholesterol triggers membrane microdomain-dependent CD44 shedding and suppresses tumor cell migration*. J Biol Chem, 2011. **286**(3): p. 1999-2007.
57. Aiello, N.M., et al., *EMT Subtype Influences Epithelial Plasticity and Mode of Cell Migration*. Dev Cell, 2018. **45**(6): p. 681-695 e4.
58. Comaills, V., et al., *Genomic Instability Is Induced by Persistent Proliferation of Cells Undergoing Epithelial-to-Mesenchymal Transition*. Cell Rep, 2016. **17**(10): p. 2632-2647.

Acknowledgements

This work has been supported by Inserm/Institut Paoli-Calmettes and grants from the AP-HM AORC Junior 2018, Canceropole PACA 2018, GIRCI Méditerranée 2019. A.A. is supported by a postdoctoral fellowship from the “Fondation ARC” (n°PDF20180507565) and the “Fondation de France” (n°00107936). We want to thanks C. Lachaud for sharing the chemidoc equipment.

Figure legends

Figure 1: Characterization and validation of the EMT induced model

Cells were grown in 3D in ULA plate for 2 days (Day-2). At day 0, the EMT and EMT-MET samples were treated with the EMT-inducing cocktail for 5 days. For EMT-MET samples, the spheroids were washed off the EMT-inducing cocktail and grown for 4 more days in normal medium. **A)** Experimental setting. **B)** Representative photos of the spheroids for the baseline, EMT, EMT-MET conditions, at days 0, 3, 5, 7 and 9. **C)** Western Blots of proteins involved in EMT: FIBRONECTIN, ZEB1, VIMENTIN, OCCLUDIN. ACTIN was used as loading control. **D)** Hierarchical clustering of triplicate samples of three conditions i.e. baseline, EMT and EMT-MET and 3,131 genes based on mRNA expression levels with standard deviation (SD)>0.25. Each row represents a gene and each column represents a sample. Robust clusters defined by pvclust with an approximately unbiased p-value>100% and identified with (an asterisk and) the associated Pearson correlation. **E)** The Consensus Molecular Subtype (CMS) classification was applied to mRNA expression profile of each sample by using the CMScaller tool from Eide et al. [21], providing a score for the four CMS subtypes (CMS1, CMS2, CMS3, and CMS4). Box plot comparing the four CMS scores according each condition (baseline, EMT or EMT-MET). The significant differences defined by one-way ANOVA post hoc Tukey test are visualized with an arrow and p-value are indicated as follows. * : $p < 0.05$, **: $p < 0.01$

Figure 2. Epithelial to Mesenchymal transition pathways, Cholesterol homeostasis and bile acid metabolism are inversely regulated by the addition and the release of the EMT-inducing cocktail

A) Sixteen gene-sets out from the MSigDB Molecular Signatures Database (GSEA) were differentially regulated in at least one comparison (q-value<1%): Baseline vs EMT or EMT

vs EMT-MET. The 3 gene sets inversely regulated in the two conditions were “*Epithelial Mesenchymal Transition*”, “*Bile Acid Metabolism*”; “*Cholesterol Homeostasis*” (white background). **B)** Heatmap of metagenes in the nine samples ordered by condition i.e. Baseline, MT and EMT-MET conditions. Metagene of the three gene sets that were significantly and oppositely deregulated in both comparisons were built using the core genes defined in GSEA analysis: “*Epithelial Mesenchymal Transition*” (14 genes); “*Bile Acid Metabolism*” (17 genes); “*Cholesterol Homeostasis*” (21 genes). **C)** Box plot comparing the three individual metagenes according each condition (baseline, EMT or EMT-MET). P-values (ANOVA post hoc Tukey test) are indicated as follows *** $p < 0.001$.

Figure 3: Epithelial to Mesenchymal transition pathways and Cholesterol homeostasis have synergic prognostic value in patients.

Patients were classified as positive or negative according to their metagenes scores. **A)** Kaplan-Meier curves for recurrence free survival (RFS) of 1887 CRC patients assessed using the log-rank test, for the 3 metagenes: “*Epithelial Mesenchymal Transition*”, “*Bile Acid Metabolism*” and “*Cholesterol Homeostasis*”. **B)** Forest plot showing the hazard ratio for survival events of each GSEA metagene and recurrence-free survival in CRC patients in univariate and multivariate analysis. A ratio greater than one indicates a poor prognosis and a ratio lower than one indicates good prognosis. The black squares correspond to significant genes and the grey ones to non-significant and the lines defined the 95% confidence interval. **C)** Kaplan-Meier curves for RFS according to four groups: “*Epithelial Mesenchymal transition*”-negative/“*Cholesterol Homeostasis*”-positive” group (green, n=452), “*Epithelial Mesenchymal transition*”-negative/“*Cholesterol Homeostasis*”-negative group (black, n=445), “*Epithelial Mesenchymal transition*”-positive/“*Cholesterol Homeostasis*”-positive group (blue, n=481), and “*Epithelial Mesenchymal transition*”-

positive/“*Cholesterol Homeostasis*”-negative group (red, n=459). **D)** Kaplan-Meier curves for survival model derived from the fusion of and *Cholesterol Homeostasis* metagenes (“*Epithelial Mesenchymal Transition*” and “*Cholesterol Homeostasis*”) in the training (n=450) and the validation (n=1387) sets.

Figure 4: Morphological changes induced with statins depending on the EMT-MET status

For these experiments, cells were grown in ULA plate for 2 days (Day-2) as dense spheroids. Two setting were then used. **A-C)** First setting: From day 0 to day 5, spheroids were either cultured with regular media (baseline), or co-treated with the EMT-inducing cocktail plus DMSO or the EMT-inducing cocktail plus simvastatin. **A)** Experimental setting. **B)** Representative photos of the spheroids in baseline, DMSO and Simvastatin conditions. **C)** Quantification of the spheroid size in arbitrary unit (no significant statistical differences).

D-F) Second setting: From day 0 to day 5, spheroids were treated with the EMT-inducing cocktail. Then, the EMT-inducing cocktail was washed out and replaced with medium, DMSO (0.5 %), Ethanol (0.5 %), Simvastatin (50 μ M), or Lovastatin (50 μ M) for 5 days. **D)** Experimental setting. **E)** Representative photos of the spheroids for each condition. **F)** Quantification of the spheroid size, in arbitrary unit. Mean values (+/- SEM) are represented as histograms.

Figure 5: Graphical summary of the potential relationship between EMT activation and the cholesterol pathway.

The mevalonate pathway leads to cholesterol synthesis. Cholesterol is involved in multiple biological homeostatic mechanisms (Bile acid, steroid hormones and vitamin D precursor, Membrane stability and rigidity, Lipid raft organization ...). Cholesterol inhibits the

773 synthesis of SREBP1, a transcription factor for the TGF β 1 signaling. TGF β 1 signaling is a
 774 key feature of the CMS4 mesenchymal class. Our data suggest that low cholesterol in a
 775 pro-EMT environment might favor the differentiation of CMS4 mesenchymal tumors, while
 776 high cholesterol favored more epithelial tumors. Genes down regulated in our Cholesterol
 777 Homeostasis metagene are written in red. Statins are inhibitors of the HMGCR enzyme.
 778
 779

780

781 **Supplementary Figure 1: Cholesterol homeostasis regulator HMGCR and DHCR7 are**
 782 **down regulated by the EMT-inducing cocktail treatment.**

783 Cells were grown in 3D in ULA plate for 2 days (Day-2). At day 0, the EMT and EMT-MET
 784 samples were treated with the EMT-inducing cocktail for 5 days. For EMT-MET samples,
 785 the spheroids were washed off the EMT-inducing cocktail and grown for 4 more days in
 786 normal medium. Cells are collected and lysed with RIPA buffer before to be subjected to a
 787 Western Blot analysis. FIBRONECTINE (FIBRO.) is a mesenchymal marker,
 788 CYTOKERATINES (pan CTK) are mostly epithelial markers, both to verify EMT induction
 789 by the EMT-inducing cocktail. DHCR7 and HMGCR are regulators of the cholesterol
 790 homeostasis pathway. Actin is the loading control.

791

792

793

794

795

796

Figure 1

A

B

C

Figure 2

Figure 3

Figure 4

Figure 5

Table 1: (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

Clinicopathological characteristics of the 2,239 primary colon cancer samples

Characteristics		N (%)
Age_Diag50	<=50	228 (12%)
	>50	1702 (88%)
Sex	female	954 (47%)
	male	1069 (53%)
Location	distal	840 (50%)
	proximal	854 (50%)
pStage	1	167 (10%)
	2	667 (41%)
	3	548 (34%)
	4	237 (15%)
Grade	1	26 (6%)
	2	353 (77%)
	3	77 (17%)
CMS	CMS1	389 (20%)
	CMS2	640 (32%)
	CMS3	343 (17%)
	CMS4	604 (31%)
Follow-up median, months (range)		43 (1-212)
5y-RFS		71% [68-73]

Table 2:

Correlations of the "EMT-CHL model"-based classes with clinicopathological variables

EMT' + 'CHL hom.' Cox model (Validation set)				
Characteristic	N	low-risk	high-risk	p-value
Age_Diag50				0.0507
<=50	139	25 (8%)	114 (13%)	
>50	1064	277 (92%)	787 (87%)	
Sex				0.00201
female	603	127 (40%)	476 (50%)	
male	668	192 (60%)	476 (50%)	
Location_2K				0.921
distal	517	130 (48%)	387 (49%)	
proximal	543	139 (52%)	404 (51%)	
pStage				3.00E-04
1	123	34 (15%)	89 (12%)	
2	466	130 (56%)	336 (44%)	
3	399	67 (29%)	332 (44%)	
4	0	0 (0%)	0 (0%)	
Grade				0.876
1	19	5 (7%)	14 (6%)	
2	259	59 (78%)	200 (80%)	
3	47	12 (16%)	35 (14%)	
CMS				3.50E-33
CMS1	269	52 (19%)	217 (23%)	
CMS2	401	138 (51%)	263 (28%)	
CMS3	212	79 (29%)	133 (14%)	
CMS4	343	3 (1%)	340 (36%)	
Follow-up median, months (range)	1387	42 (1-192)	42 (1-203)	0.387
5y-RFS	1387	74% [70-78]	68% [64-72]	1.68E-02

Table 3: Uni- and multivariate analyses for RFS in the validation set

RFS		Univariate			Multivariate		
		N	HR [95%CI]	p-value	N	HR [95%CI]	p-value
Age_Diag50	>50 vs. <=50	1203	0.98 [0.70-1.37]	0.894			
Sex	male vs. female	1271	1.09 [0.87-1.35]	0.458			
Location	proximal vs. distal	1060	1.00 [0.79-1.26]	0.998			
pStage	2 vs. 1	988	3.48 [1.41- 8.62]	3.09E-10	861	2.53 [1.01-6.33]	4.78E-02
	3 vs. 1		7.74 [3.16-18.93]		861	5.77 [2.35-14.20]	1.36E-04
	4 vs. 1		NA [NA- NA]		861	<NA> [NA-NA]	<NA>
Grade	2 vs. 1	325	1.24 [0.39-3.97]	0.569			
	3 vs. 1		1.70 [0.47-6.12]				
CMS	CMS2 vs. CMS1	1225	0.75 [0.54-1.03]	2.29E-03	861	0.69 [0.43-1.10]	0.121
	CMS3 vs. CMS1		0.91 [0.64-1.30]		861	1.13 [0.68-1.90]	0.636
	CMS4 vs. CMS1		1.28 [0.94-1.73]		861	1.31 [0.87-1.97]	0.196
EMT-CHL model	high- vs. low-risk	1387	1.35 [1.04-1.75]	2.51E-02	861	1.7 [1.02-2.83]	4.02E-02

Table 4:

Top 15 drug classes identified with connectivity map (L1000), 14 EMT vs. 21g CHL GSEA core genes

Drug class (moa)	Number of significant pertubagen signatures	Normalised connectivity score (ncs): average ncs	ncs average 95% CI	reproducibility of ncs per drug class (t-test)		
				t	p.value	score
Dopamine receptor antagonist	93	-1.64	[-1.67,-1.61]	-98.47	4.83E-95	-94.316
EGFR inhibitor	80	-1.65	[-1.74,-1.55]	-33.31	2.86E-48	-47.544
Serotonin receptor antagonist	44	-1.63	[-1.68,-1.58]	-62.43	7.92E-44	-43.101
PDGFR inhibitor	37	-1.65	[-1.71,-1.59]	-57.98	3.75E-37	-36.426
Bcr-Abl inhibitor	33	-1.67	[-1.72,-1.62]	-63.64	2.85E-35	-34.545
Abl inhibitor	33	-1.67	[-1.72,-1.62]	-63.64	2.85E-35	-34.545
Histamine receptor antagonist	33	-1.61	[-1.66,-1.56]	-62.66	4.67E-35	-34.331
KIT inhibitor	34	-1.66	[-1.72,-1.6]	-56.25	2.34E-34	-33.631
Adrenergic receptor antagonist	30	-1.61	[-1.66,-1.55]	-58.08	1.46E-31	-30.836
HMGCR inhibitor / statin	31	-1.67	[-1.74,-1.61]	-53.31	2.79E-31	-30.554
Src inhibitor	30	-1.71	[-1.77,-1.64]	-55.4	5.65E-31	-30.248
Calcium channel blocker	24	-1.66	[-1.72,-1.61]	-61.46	5.13E-27	-26.29
Tricyclic antidepressant	26	-1.7	[-1.77,-1.63]	-48.88	2.45E-26	-25.611
Estrogen receptor antagonist	25	-1.68	[-1.75,-1.62]	-52.34	2.99E-26	-25.524
VEGFR inhibitor	50	-1.63	[-1.78,-1.47]	-21.1	3.04E-26	-25.517